Consultation: actions from September 2023 CRG meeting

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their September 2023 meeting. Actions in this consultation include:

  • Tadalafil 5mg once daily – remove from DNP list and assign GREEN RAG status
  • Herbal treatments – DNP listing amended to “herbal treatments and other natural products”, in line with NHS England guidance
  • Cipaglucosidase alfa – add to formulary as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Friday 27th October 2023. To take part, visit the consultations page.


Consultation: actions from August 2023 CRG meeting

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their August 2023 meeting. Actions in this consultation include:

  • Sodium chloride 5% eye drops – RED
  • Bempedoic acid – comments sought regarding a change to GREEN
  • Steroid eye drops (betamethasone 0.1%, dexamethasone 0.1%, prednisolone 0.03%, 0.1%, 0.5% & 1%, fluorometholone 0.1%) – GREEN (specialist initiation)
  • Rimegepant for preventing migraine – GREEN (specialist initiation) OR GREEN (specialist advice)
  • Semaglutide for overweight and obesity in young people aged 12-17 years – Do Not Prescribe.

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Friday 22nd September 2023. To take part, visit the consultations page.


Consultation: updated HCD inflammatory bowel disease pathway

Following development by a clinical working group and review by CRG, we now seek comments on the draft update of the GMMMG High Cost Drugs Inflammatory Bowel Disease Pathway.

The consultation will run for 6 weeks, closing at 5pm on 30th August. To take part, please visit the consultations page.


Consultation: actions from July CRG meeting

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their July 2023 meeting. Actions in this consultation include:

  • Bulevirtide for chronic hepatitis D – add to formulary as RED
  • Esketamine for major depressive disorder in adults at imminent risk of suicide – update existing DNP listing to include this indication
  • Dapagliflozin for chronic heart failure with preserved or mildly reduced ejection fraction – add to formulary as GREEN (following specialist advice)
  • Upadacitinib for Crohn’s disease – add to formulary as RED
  • Deucravactinib for plaque psoriasis – add to formulary as RED
  • Emollient bath additives – update DNP listing to include reference to new NICE ‘do not do’ recommendation

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Tuesday 29th August 2023. To take part, visit the consultations page.


Consultation: actions from May CRG meeting

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their May 2023 meeting. Actions in this consultation include:

  • Fosfomycin 3g oral sachets for uncomplicated UTI in non-pregnant women – to be GREEN
  • Tezepelumab for severe asthma – to be RED

All links to MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Friday 23rd June 2023.


Consultation: actions from January 2023 meeting of CRG

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the January 2023 CRG meeting.

Actions in this consultation include:

  • Avatrombopag added to formulary as a RED drug for primary chronic immune thrombocytopenia.
  • Esketamine nasal spray for treatment-resistant depression added to the DNP list.

All links to MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Monday 6th March 2023.


Consultation: actions from December meeting of CRG

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the December 2022 CRG meeting.

Actions in this consultation include:

  • Donepezil, galantamine and rivastigmine for mild to moderate Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease: Green (specialist advice)
  • Cyclogest added to formulary as an option for vaginal micronised progesterone for prevention of miscarriage

All links to MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Thursday 26th January 2023.